
Derma Sensor is a Miami-based health technology company focused on improving skin cancer detection through its innovative handheld device. The device utilizes elastic scattering spectroscopy and machine learning to provide non-invasive, objective evaluations of skin lesions, significantly enhancing early detection rates. With a mission to improve healthcare outcomes and reduce costs, Derma Sensor aims to equip primary care providers with effective tools for skin cancer assessment, addressing the critical need for accessible skin cancer evaluations in the healthcare system. The company has demonstrated strong clinical validation, showing a 97% sensitivity in detecting skin cancers, and has been actively involved in clinical studies to refine its technology and expand its market presence.

Derma Sensor is a Miami-based health technology company focused on improving skin cancer detection through its innovative handheld device. The device utilizes elastic scattering spectroscopy and machine learning to provide non-invasive, objective evaluations of skin lesions, significantly enhancing early detection rates. With a mission to improve healthcare outcomes and reduce costs, Derma Sensor aims to equip primary care providers with effective tools for skin cancer assessment, addressing the critical need for accessible skin cancer evaluations in the healthcare system. The company has demonstrated strong clinical validation, showing a 97% sensitivity in detecting skin cancers, and has been actively involved in clinical studies to refine its technology and expand its market presence.
Product: Handheld optical spectroscopy device + ML for skin lesion cancer risk assessment
Headquarters: Miami, United States
Clinical performance: Reported 97% sensitivity in detecting skin cancers (clinical validation cited)
Market: Sells to primary care providers, clinicians, and health systems (B2B medical device)
Funding: Multiple rounds (Crunchbase lists 9 rounds); investors include Ceros Capital Markets, GenHenn Venture, Pier 70 Ventures, Miami Angels
Early detection of skin cancer and improving diagnostic access in primary care.
2009
Biotechnology
Series A announced with participants including Maurice Ferre, Ernest Bachrach, Alberto Beeck
“Backed by a mix of venture funds and angel/institutional investors including Ceros Capital Markets, GenHenn Venture, Pier 70 Ventures, Miami Angels”